La cadena de opciones muestra datos clave de las opciones de acciones de Kazia Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Kazia Therapeutics..

Kazia Therapeutics (NASDAQ:KZIA) Bolsa, Cadena de Opciones

KAZIA THERAPEUTICS-SPON ADR

Kazia Therapeutics

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics Ltd

Press Releases

Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)

News

Small-Cap Disruptors KZIA, SNYR, HSDT, TRNR, PRSO Lead Momentum – More Microcap Stocks Inside

Small Cap

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

Opinion

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

Contracts

Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy

Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG

Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen

Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

AMZN

CLDI

COST

HSDT

IMNN

IMRX

INEO

KBSX

KZIA

NUVB

ONCY

PNPNF

PRSO

SNYR

TRNR

TSX:ONC

TSXV:PNPN

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

Aprea Therapeutics

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Entero Therapeutics

Ernexa Therapeutics

Evogene

Galecto

Imunon

IN8bio

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Mustang Bio

Marker Therapeutics

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Xenetic Biosciences

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

Kazia Therapeutics

Kazia Therapeutics (KZIA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL